Celgene announced that analyses of both Phase III Special Protocol Assessment (SPA) multiple myeloma trials exceeded the pre-specified value for stopping the trials.
WebProWorld
Celgene announced that analyses of both Phase III Special Protocol Assessment (SPA) multiple myeloma trials exceeded the pre-specified value for stopping the trials.